- Home
- RVPHW vs FINS Comparison
RVPHW vs FINS Comparison
Compare RVPHW & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- FINS
- Stock Information
- Founded
- RVPHW 2018
- FINS 2019
- Country
- RVPHW United States
- FINS United States
- Employees
- RVPHW 14
- FINS N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- RVPHW Health Care
- FINS Finance
- Exchange
- RVPHW Nasdaq
- FINS Nasdaq
- Market Cap
- RVPHW N/A
- FINS N/A
- IPO Year
- RVPHW N/A
- FINS N/A
- Fundamental
- Price
- RVPHW $0.03
- FINS N/A
- Analyst Decision
- RVPHW
- FINS
- Analyst Count
- RVPHW 0
- FINS 0
- Target Price
- RVPHW N/A
- FINS N/A
- AVG Volume (30 Days)
- RVPHW 22.4K
- FINS 78.0K
- Earning Date
- RVPHW 03-14-2025
- FINS 01-01-0001
- Dividend Yield
- RVPHW N/A
- FINS 9.97%
- EPS Growth
- RVPHW N/A
- FINS N/A
- EPS
- RVPHW N/A
- FINS N/A
- Revenue
- RVPHW N/A
- FINS N/A
- Revenue This Year
- RVPHW N/A
- FINS N/A
- Revenue Next Year
- RVPHW N/A
- FINS N/A
- P/E Ratio
- RVPHW N/A
- FINS N/A
- Revenue Growth
- RVPHW N/A
- FINS N/A
- 52 Week Low
- RVPHW $0.13
- FINS $11.61
- 52 Week High
- RVPHW $0.15
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- FINS 61.73
- Support Level
- RVPHW N/A
- FINS $12.71
- Resistance Level
- RVPHW N/A
- FINS $12.84
- Average True Range (ATR)
- RVPHW 0.00
- FINS 0.13
- MACD
- RVPHW 0.00
- FINS 0.05
- Stochastic Oscillator
- RVPHW 0.00
- FINS 94.92
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.